Furosemide formulations

WO2026152113A1PCT designated stage Publication Date: 2026-07-16SCPHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
SCPHARMACEUTICALS INC
Filing Date
2026-01-13
Publication Date
2026-07-16

AI Technical Summary

Technical Problem

Existing furosemide formulations face challenges in achieving stable, high concentration, and physiologically balanced solutions suitable for subcutaneous delivery, due to issues with solubility, stability, and pH, which can cause pain and discomfort during injection.

Method used

The development of liquid pharmaceutical formulations containing furosemide with specific solubilizers and buffers such as ammonium acetate, sodium bicarbonate, arginine, and glycine, along with optional pH adjusters like potassium hydroxide or sodium hydroxide, to create stable, concentrated solutions suitable for subcutaneous administration.

Benefits of technology

The formulations provide chemically and physically stable furosemide solutions at appropriate pH and osmolality, enabling safe and effective subcutaneous delivery with reduced injection volume and discomfort.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000005_0001
    Figure IMGF000005_0001
  • Figure IMGF000038_0001_TABLE
    Figure IMGF000038_0001_TABLE
  • Figure IMGF000038_0002_TABLE
    Figure IMGF000038_0002_TABLE
Patent Text Reader

Abstract

Disclosed herein, in part, are liquid pharmaceutical formulations containing furosemide for delivering to a patient via subcutaneous injection. Methods of treating conditions such as congestion due to fluid overload, edema, and hypertension in a patient in need thereof are also provided.
Need to check novelty before this filing date? Find Prior Art